MHRA approves capivasertib for treatment of advanced breast cancer
Capivasertib is an oral pill given with fulvestrant, a hormonal therapy, as an alternative treatment to endocrine-based regimens.
Capivasertib works by blocking the effects of AKT kinase proteins, which enable cancer cell growth
Shutterstock.com
The Medicines and Healthcare products Agency (MHRA) has authorised the use of a new drug for the treatment of locally advanced or metastatic HR-positive, HER 2-negative breast cancer.
Get unlimited access to all content
You’ve reached your limit of premium articles on The Pharmaceutical Journal for this month.
